Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial-Reference-Cited by-同舟云学术

Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial

Published:2024-06-01 Issue:8 Volume:30 Page:2181-2188
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Jiang Rong^ORCID,Feng Yanling^ORCID,Chen Yulian^ORCID,Cheng Xi,Shi Tingyan^ORCID,Gao Wen,Jia Huixun^ORCID,Jiang Shiyang^ORCID,Guo Yi^ORCID,Huang Xiao,Tu Dongsheng^ORCID,Zhang Yuqin,Yang Huijuan,Zhang Ping,Liu Jihong,Zhu Jianqing,Zang Rongyu^ORCID,

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-02981-0.pdf

Reference26 articles.

1. Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12–49 (2024).

2. Bristow, R. E. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 41, 4065–4076 (2023).

3. Reuss, A. et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int. J. Gynecol. Cancer 29, 1327–1331 (2019).

4. Jiang, R. et al. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. J. Gynecol. Oncol. 31, e86 (2020).

5. du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115, 1234–1244 (2009).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biology as a driver in therapeutic choices for ovarian cancer;International Journal of Gynecologic Cancer;2024-08-28

2. Role of secondary cytoreduction in relapsed ovarian cancer;International Journal of Gynecologic Cancer;2024-07-31

3. Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials;Cancers;2024-07-22